Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BASI Bioanalytical Systems (BASI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Bioanalytical Systems Stock (NASDAQ:BASI) 30 days 90 days 365 days Advanced Chart Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Bioanalytical Systems alerts:Sign Up Key Stats Today's Range$3.10▼$3.7850-Day Range$14.04▼$22.5052-Week Range$3.05▼$21.08Volume2.29 million shsAverage Volume122,925 shsMarket Capitalization$35.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. BioVaxys has an agreement with Inotiv to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.Read More… When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Receive BASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioanalytical Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address BASI Stock News HeadlinesSapio Sciences enhances lab informatics platform with new immunogenicity bioanalysis featuresOctober 18, 2024 | msn.comWhat a Basic Metabolic Panel (BMP) MeasuresApril 29, 2024 | yahoo.comWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.November 21, 2024 | DTI (Ad)10 Analysts Assess NIO: What You Need To KnowApril 2, 2024 | markets.businessinsider.comWhat Is Bioprocessing? Here Are the BasicsMarch 27, 2024 | msn.comWhat 11 Analyst Ratings Have To Say About Analog DevicesFebruary 12, 2024 | markets.businessinsider.comDemystifying Airbnb: Insights From 13 Analyst ReviewsJanuary 29, 2024 | markets.businessinsider.com7 Best B2B Database Providers for 2024January 26, 2024 | techrepublic.comSee More Headlines BASI Stock Analysis - Frequently Asked Questions How were Bioanalytical Systems' earnings last quarter? Bioanalytical Systems, Inc. (NASDAQ:BASI) released its earnings results on Monday, February, 8th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.16. The firm earned $17.89 million during the quarter. Bioanalytical Systems had a negative trailing twelve-month return on equity of 42.74% and a negative net margin of 7.75%. Read the conference call transcript. What other stocks do shareholders of Bioanalytical Systems own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioanalytical Systems investors own include Meta Platforms (META), Enphase Energy (ENPH), Overstock.com (OSTK), Riot Platforms (RIOT), Twilio (TWLO), Boeing (BA) and NVIDIA (NVDA). Company Calendar Last Earnings2/08/2021Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial Physical Research Sub-IndustryN/A Current SymbolNASDAQ:BASI CUSIPN/A CIK720154 Webwww.basinc.com Phone765-463-4527FaxN/AEmployees397Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,680,000.00 Net Margins-7.75% Pretax MarginN/A Return on Equity-42.74% Return on Assets-6.38% Debt Debt-to-Equity Ratio2.49 Current Ratio0.48 Quick Ratio0.46 Sales & Book Value Annual Sales$60.47 million Price / Sales0.59 Cash Flow$0.01 per share Price / Cash Flow558.40 Book Value$0.69 per share Price / Book4.65Miscellaneous Outstanding Shares11,131,000Free FloatN/AMarket Cap$35.73 million OptionableNot Optionable Beta1.92 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BASI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioanalytical Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioanalytical Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.